Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study - Aix-Marseille Université Access content directly
Journal Articles Breast Cancer Research and Treatment Year : 2017

Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study

Anthony Gonçalves
Jean Classe
  • Function : Author
Monique Cohen
  • Function : Author
Fabien Reyal
Christophe Scherer
  • Function : Author
Pierre Colombo
  • Function : Author
Roman Rouzier
  • Function : Author
Emile Darai
  • Function : Author
Jean Garbay
  • Function : Author
Jean Boher
  • Function : Author
Gilles Houvenaeghel

Domains

Cancer
No file

Dates and versions

hal-03623719 , version 1 (29-03-2022)

Identifiers

Cite

Alexandre de Nonneville, Anthony Gonçalves, Christophe Zemmour, Jean Classe, Monique Cohen, et al.. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study. Breast Cancer Research and Treatment, 2017, 162 (2), pp.307-316. ⟨10.1007/s10549-017-4136-5⟩. ⟨hal-03623719⟩
13 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More